Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2018

View Archived Issues

Novel aCD40E vaccine demonstrates immunogenicity in vivo

Arcus Biosciences enrolling healthy volunteers in phase I study of AB-680

IP6 analogues explored as treatment for kidney stones

Positive topline results presented from phase III program evaluating FMX-103

New gene therapy acting on GABA-A receptor improves cognitive deficits related to schizophrenia

Can't we all just get along? Targeting innate immunity prevents transplant rejection

MicroRNA 31 levels predict response of patients with colon cancer to adjuvant cetuximab therapy

PLB-002, a SUMO mimetic polypeptide, shows inhibition of tau toxicity and motor/memory impairment

Kynurenine 3-monooxygenase promotes colorectal cancer tumorigenesis

PAI-1 antagonist TM5A15 demonstrates AD protection in vivo

BD-442618 reduces gambling-like behavior in rats

Preliminary results of phase I study of MK-1454/pembrolizumab for advanced solid tumors or lymphomas

Discovery and optimization of Aurora B-selective SYK inhibitors as topical agents for skin diseases

DS-003 vaginal microbicide tablet achieves protective levels after administration to healthy women

Phase III results of the IL-17A antagonist ixekizumab for radiographic axial spondyloarthritis

Sunshine Lake Pharma initiates phase I trial of litapiprant

New phase I trial in China studies ZSP-1273 in healthy subjects

Potent antileukemia and antimyeloma activity by hedgehog pathway signaling inhibitor HH-78

Voyager Therapeutics reports longer-term data from phase Ib study of VY-AADC in Parkinson's disease

PledPharma initiates phase III program with PledOx

Immunomedics and AstraZeneca to study sacituzumab and durvalumab in metastatic NSCLC

Enrollment open in phase II study of Blautix for IBS

Visterra initiates first-in-human study with VIS-649 for IgA nephropathy

AstraZeneca initiates first-in-human study of AZD-9833 in advanced breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...